Plainfield, INNCT07144852Now EnrollingIRB Ready

Actinic Keratosis Clinical Trial in Plainfield, IN

Access cutting-edge actinic keratosis treatment through this clinical trial at a research site in Plainfield. Study-provided care at no cost to qualified participants.

Sponsored by Sun Pharmaceutical Industries, Inc.

Quick Self-Assessment

See if you qualify for this Plainfield location

Preparing your pre-screening questions…

Expert Care in Plainfield

Access actinic keratosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related actinic keratosis treatment provided free

Apply for This Plainfield Location

Check if you qualify for this actinic keratosis clinical trial in Plainfield, IN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Plainfield

    Convenient for IN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Plainfield site if eligible
  4. 4Begin participation

About This Actinic Keratosis Study in Plainfield

This Phase 3, randomized, multi-center, evaluator-blind, vehicle-controlled study evaluates the efficacy and safety of reformulated Levulan Kerastick (aminolevulinic acid HCl 20%) combined with photodynamic therapy (PDT) for field-directed treatment of actinic keratosis (AK) on the upper extremities. Approximately 260 adult patients with 4-8 mild to moderate AK lesions on one arm will be randomized to receive either active treatment or vehicle control, followed by exposure to blue light. During the study, up to 2 PDT sessions may be administered depending on the clearance of lesions. The primary endpoint is complete clearance rate (CCR) at Week 12. Secondary endpoints include AK clearance rate (AKCR), partial clearance, change in total lesion count and area, recurrence rate, cosmetic response, and patient satisfaction. Safety assessments include adverse events, local skin reactions, vital signs, and lab tests.

Sponsor: Sun Pharmaceutical Industries, Inc.

Who Can Participate

Inclusion Criteria

Patient is a male or non-pregnant female aged 18-85 years.
Patient must have 4-8 mild to moderate actinic keratosis (AK) lesions (Olsen grade 1 or 2) in a single treatment area on their Index arm, each measuring up to 1 cm in diameter and spaced at least 1 cm apart. \[The treatment area should be approximately 25 cm², located on the extensor surface of only one of the upper extremities that is selected as the Index arm\]
Patients must be in good general health, avoid sunbathing or tanning devices, and maintain a consistent skincare routine throughout the study.
Patient is willing to stop using all topical products within the Treatment Area within 8 hours of a scheduled clinic visit with an efficacy evaluation.
Women of childbearing potential must use highly effective contraception; men with such partners must use barrier methods unless surgically sterile.

Exclusion Criteria

Presence of Olsen grade 3 AK, untreated or suspicious skin cancers, or significant skin abnormalities (e.g., psoriasis, eczema) in the treatment area.
Active herpes simplex infection or history of ≥2 outbreaks in the treatment area within the past year.
History of cutaneous photosensitization, porphyria, photodermatosis, or hypersensitivity to porphyrins.
Positive human immunodeficiency virus (HIV) test result, hepatitis B surface (HBS) antigen, or hepatitis C virus (HCV) test result
Immunosuppressed status (e.g., HIV, organ transplant) or known coagulation defects.
Use of specific topical therapies (e.g., retinoids, steroids, cryotherapy, PDT, chemical peels) on the treatment area within 2 days to 8 weeks prior to randomization.
Recent use of certain systemic therapies (e.g., corticosteroids, immune-modulators, retinoids, cytotoxic drugs) within 6 weeks to 6 months prior to randomization.
Recent use of hypericin or other phototoxic/photoallergic medications (e.g., tetracyclines, psoralenes, St. John's wort) within 8 weeks of randomization.
Clinically significant or unstable illnesses, or history of alcohol/drug abuse in the past year.
Pregnancy/lactation, recent or current participation in another clinical study, or any other condition deemed unsuitable by the Investigator.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Plainfield?

Yes, this clinical trial (NCT07144852) has an active research site in Plainfield, IN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Actinic Keratosis Treatment Options in Plainfield, IN

If you're searching for actinic keratosis treatment options in Plainfield, IN, this clinical trial (NCT07144852) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Plainfield research site is actively enrolling participants for this clinical trial. You'll receive care from experienced actinic keratosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all actinic keratosis clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Plainfield, IN

See all rheumatoid arthritis clinical trials recruiting in Plainfield — not just this study.

Browse Rheumatoid Arthritis Trials in Plainfield →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Plainfield?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Plainfield, IN